Special Issue "Emerging molecules for leishmaniasis therapy"
A special issue of Molecules (ISSN 1420-3049).
Deadline for manuscript submissions: 30 November 2020.
Interests: Solid-solid reactions by mechanochemistry; Cyclodextrin inclusion compounds, Solubilisation of active pharmaceutical ingredients (APIs), Local therapeutic systems for osteosarcoma and osteoporosis, Antioxidant flavonoids and their Ru(II) complexes, Natural and metallo-organic compounds for cytotoxic and biocidal activities; Innovative medicines for leishmaniasis based on inorganic complexes and cyclodextrins
Special Issues and Collections in MDPI journals
Interests: photodynamic therapy of cancer; organic synthesis of fine chemicals and pharmaceutical compounds; drug development; porphyrin and hydroporphyrin synthesis; photophysics and photochemistry of tetrapyrroles; near-infrared photosensitizers; water-soluble porphyrinoids and environmntal applications; dye-sensitized solar cells; biomedical applications of tetrapyrrolic macrocycles; translational research
Interests: Biochemistry; Organic Chemistry; Synthetic Chemistry; Heterocyclic Compounds (ex. Chromone, Quinoline and Acridine Derivatives); Biologically Active Compounds; Drug Design and Development; Multi-Target-Directed-Ligands (MTDLs); Neurodegenerative Diseases; Neglected Diseases; Leishmaniasis
Leishmaniasis is a parasitic infection caused by various species of the Leishmania genus. Known to have affected humankind for thousands of years, leishmaniasis has typically remained endemic in warm climate areas of Africa, South America, India, and the Middle East. For its geographical distribution, and for the troubling short range of medicines avaialble to treat it, leishmaniasis was deemed as a Neglected Tropical Disease by the WHO. Presently, the disease is tending toward expansion, either due to global warming that is opening the doors for it to spread to Europe and North America, or due to increases in sociopolitical tension and civil war in Northern Africa and Middle-Eastern regions. As a response, the scientific community across the globe is intensifying efforts to find new active molecules against the disease. With this Special Issue, we are opening a forum for the presentation of the newest and most exciting results and perspectives on leishmanicidal drug design and discovery, from natural products to organic small molecules and metal complexes.
Dr. Susana Santos Braga
Dr. Carlos Monteiro
Dr. Carlos Silva
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Neglected diseases
- Protozoan parasite Leishmania
- Drug design and discovery
- Medicinal chemistry
- Drug resistance
- Multitarget compounds
- Metal complexes
- Natural products
- Combination therapy
- Photodynamic therapy